Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sujatha Chilakala
08.13.26 -- Reshoring Pressure Meets Manufacturing Reality
Webinar: A CCS is a purpose-built machine, not a black box: Understand the workings Discover how to transform your contamination control strategy from a static compliance document into a dynamic, data-driven system. In this CAI webinar, learn how to connect operational evidence, monitoring data, and risk assessments to drive continuous improvement, strengthen contamination control decisions, and maintain a defensible CCS throughout its lifecycle while fostering a proactive quality culture.
02.18.26 -- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
Join us for February's Bio-Expo Live, a three-day virtual event designed to empower biopharma professionals with the chance to conveniently explore the newest equipment and offerings in Upstream Bioprocessing, Downstream Bioprocessing and Bioprocess Quality, Data, and Analytical Solutions.
Aggregate Analysis Of Insulin Analogues Using A Biozen dSEC-1 SEC Column
By Sujatha Chilakala, Ph.D., and Lucia Geis-Asteggiante, Ph.D. This content is brought to you by Phenomenex, a Danaher Operating Company. Insulin analogues, like native insulin, are therapeutic peptides essential for regulating blood glucose levels. However, both native insulin and its analogues can form aggregates during storage or in vivo, which may decrease absorption and uptake, making the assessment of purity crucial.
Aggregate Analysis Of Tirzepatide Using A Biozen dSEC-1 SEC Column
By Sujatha Chilakala, Ph.D., and Lucia Geis-Asteggiante, Ph.D. This content is brought to you by Phenomenex, a Danaher Operating Company. Tirzepatide, a dual GIP and GLP-1 receptor agonist used for managing type 2 diabetes and obesity, is a large, hydrophobic peptide prone to aggregation under various stress conditions. Since aggregation can compromise product safety and efficacy, detecting and quantifying it is a critical step in quality control.
Aggregate Analysis Of Semaglutide Using A Biozen dSEC-1 SEC Column
By Sujatha Chilakala, Ph.D., and Lucia Geis-Asteggiante, Ph.D. This content is brought to you by Phenomenex, a Danaher Operating Company. Semaglutide, a synthetic peptide therapeutic used for managing type 2 diabetes and obesity, is susceptible to aggregation, which can reduce its safety and efficacy. Monitoring this aggregation is critical, typically performed using Size Exclusion Chromatography (SEC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sujatha
Contact Sujatha, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack